- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Arrowhead Pharmaceuticals (ARWR)
Company Profile
| Quarter (USD) | Dec 25 | Sep 25 | Jun 25 | Mar 25 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 25 | Sep 24 | Sep 23 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 201.64 mm | 201.64 mm | 201.64 mm | 201.64 mm | 201.64 mm | 201.64 mm |
| Cash burn (monthly) | 8.30 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 10.54 mm | n/a | n/a | n/a | n/a | n/a |
| Cash remaining | 191.10 mm | n/a | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 23.0 | n/a | n/a | n/a | n/a | n/a |
| 13F holders | Current |
|---|---|
| Total holders | 272 |
| Opened positions | 44 |
| Closed positions | 44 |
| Increased positions | 91 |
| Reduced positions | 86 |
| 13F shares | Current |
|---|---|
| Total value | 1.81 tn |
| Total shares | 99.79 mm |
| Total puts | 490.10 k |
| Total calls | 520.70 k |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK BlackRock | 16.18 mm | $304.15 bn |
| Vanguard | 12.18 mm | $229.06 bn |
| Avoro Capital Advisors | 11.11 mm | $208.89 bn |
| STT State Street | 6.02 mm | $113.11 bn |
| Slate Path Capital | 5.23 mm | $98.36 bn |
| FMR | 5.10 mm | $95.90 bn |
| Geode Capital Management | 2.95 mm | $55.57 bn |
| Siren, L.L.C. | 2.90 mm | $54.55 bn |
| T. Rowe Price Investment Management | 2.51 mm | $47.14 mm |
| Norges Bank | 2.05 mm | $38.62 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Jan 26 | James C Hamilton | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 246,958 |
| 6 Jan 26 | Daniel Joseph Apel | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 176,200 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 547,408 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Gift | Dispose G | No | No | 0 | 440 | 0.00 | 472,408 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Gift | Dispose G | No | No | 0 | 440 | 0.00 | 472,848 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Gift | Dispose G | No | No | 0 | 540 | 0.00 | 473,288 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Gift | Dispose G | No | No | 0 | 540 | 0.00 | 473,828 |
| 6 Jan 26 | Patrick O'Brien | Common Stock | Gift | Dispose G | No | No | 0 | 540 | 0.00 | 474,368 |
| 5 Jan 26 | James C Hamilton | Common Stock | Sell | Dispose S | No | Yes | 68 | 309 | 21.01 k | 171,958 |
| 5 Jan 26 | James C Hamilton | Common Stock | Sell | Dispose S | No | Yes | 65.97 | 437 | 28.83 k | 172,267 |